Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01555463
First received: March 13, 2012
Last updated: December 28, 2015
Last verified: December 2015

March 13, 2012
December 28, 2015
September 2012
January 2014   (final data collection date for primary outcome measure)
  • Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    Static evaluation of overall severity of papulopustular rosacea at a given time: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. Therapeutic success is defined as an IGA score of clear or minimal.
  • Nominal Change From Baseline in Inflammatory Lesion (IL) Count at End of Treatment (LOCF) [ Time Frame: Baseline and end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    The mean (standard deviation) change from baseline in the inflammatory lesion count at the end of treatment is provided.
  • Efficacy of Azelaic Acid Foam 15% [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Evaluation by therapeutic success rate according to Investigators Global Assessment
  • Efficacy of Azelaic Acid Foam 15% [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Evaluation by change in inflammatory lesion count
Complete list of historical versions of study NCT01555463 on ClinicalTrials.gov Archive Site
  • Percent Change From Baseline in Inflammatory Lesion Count at End of Treatment (LOCF) [ Time Frame: Baseline and end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    The mean (standard deviation) percentage change in inflammatory lesion count from baseline to end of study is provided.
  • Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Response at End of Treatment (LOCF) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    Participants achieving a clear, minimal, or mild IGA at the end of treatment were considered as 'responder'. Participants with an IGA of moderate or severe at the end of treatment were considered as 'non-responder'. Participants who prematurely withdraw from study treatment because of lack of efficacy were coded as 'non-responders'. The percentage of responders is presented.
  • Grouped Changes From Baseline in Erythema Intensity Score at End of Treatment (LOCF) [ Time Frame: Baseline and end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    Erythema was rated as: clear or almost clear; mild; moderate; or severe. For the assessment of the grouped change in erythema ratings, the baseline examination was used to group into 'improved', 'no change', or 'worsened'. A participant was considered to have an 'improved' erythema rating if the erythema rating was lower compared to the baseline rating, 'no change' if the rating was identical, and 'worsened' if the rating was higher. The percentage of participants in each of these categories is presented.
  • Percentage of Participants With Investigator's Global Assessment (IGA) Scores at End of Treatment (LOCF) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    The IGA consists of 5 scores: 1) Clear: no papules and/or pustules; no erythema; 2) Minimal: rare papules and/or pustules; faint up to but not including mild erythema; 3) Mild: few papules and/or pustules; mild erythema; 4) Moderate: pronounced number of papules and/or pustules (but less than numerous papules and/or pustules); moderate erythema; 5) Severe: numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate to severe erythema. The percentage of participants with each score at the end of treatment is provided.
  • Nominal Value of Inflammatory Lesion Count at End of Treatment (LOCF) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    The mean (standard deviation) lesion count at the end of treatment is provided.
  • Percentage of Participants With Erythema Intensity Score at End of Treatment (LOCF) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    The percentage of participants in each rating category of erythema (clear or almost clear; mild; moderate; severe) at the end of treatment is provided.
  • Grouped Changes From Baseline in Telangiectasia Intensity Score at End of Treatment (LOCF) [ Time Frame: Baseline and end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    Telangiectasia was rated as: no; mild; moderate; or severe. At the end of study, a participant was considered to have an 'improved' telangiectasia rating if the telangiectasia rating was lower compared to the baseline rating, 'no change' if the rating was identical, and 'worsened' if the rating was higher. The percentage of participants in each category is presented.
  • Percentage of Participants With Facial Skin Color Rating at End of Treatment (LOCF) [ Time Frame: At end of treatment (LOCF), up to 12 weeks ] [ Designated as safety issue: No ]
    Facial skin color (as compared with skin outside the treatment area) was rated as: normal; barely visible skin lightening; mild skin lightening; moderate skin lightening; severe skin lightening. The percentage of participants in each category of facial skin color at the end of study is presented.
  • Participants' Global Assessment of Treatment Response at End of Treatment [ Time Frame: At end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    At the end of treatment, participants assessed the change of papulopustular rosacea from baseline (how it looked, felt, appeared to others) as excellent improvement, good improvement, fair improvement, no improvement, or worse. The number of participants in each category of this assessment is presented.
  • Participants' Global Assessment of Tolerability at End of Treatment [ Time Frame: At end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    At the end of treatment, participants provided their opinion on local tolerability of the investigational product as excellent, good, acceptable despite minor irritation, less acceptable due to continuous irritation, non-acceptable, or no opinion. The number of participants in each category of this assessment is presented.
  • Participants' Opinion on Cosmetic Acceptability at End of Treatment [ Time Frame: At end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    At the end of treatment, participants provided their opinion on cosmetic acceptability of the investigational product as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented.
  • Participants' Opinion on Practicability of Product Use in Facial Areas Next to the Hairline at End of Treatment [ Time Frame: At end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    At the end of treatment, participants provided their opinion on the practicability of the use of the investigational product in facial areas next to the hairline as very good, good, satisfactory, poor, or no opinion. The number of participants in each category of this assessment is presented.
  • Change From Baseline in Rosacea Quality of Life (RosaQoL) Questionnaire at End of Treatment - Overall Quality of Life Score [ Time Frame: Baseline and end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    The Rosacea Quality of Life (RosaQoL) is a questionnaire to evaluate the effect of rosacea on a participant's quality of life. Each of the 21 items in this questionnaire asks about the frequency with which a particular aspect of living with rosacea affects the participant: possible responses for each item are "never" (score=1), "rarely" (score=2), "sometimes" (score=3), "often" (score=4), or "all the time" (score=5). The overall score is the sum of the results from all 21 questions, with possible scores ranging from 21 (best) to 105 (worst); the higher the score, the more quality of life is impaired. The mean (standard deviation) of the change, defined as end of treatment overall score minus baseline overall score, is presented.
  • Number of Participants With Change From Baseline in Dermatology Life Quality Index (DLQI) Questionnaire at End of Treatment - Overall Score [ Time Frame: Baseline and end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    The Dermatology Life Quality Index (DLQI) is a questionnaire consisting of a set of 10 questions that evaluate the degree to which the participant's skin has affected certain behaviors and quality of life over the past week. Possible responses to each question are: "very much" (question 7: "yes") (score=3), "a lot" (score=2), "a little" (score=1), or "not at all"/"not relevant" (score=0). The DLQI overall score is the sum of the results from all 10 questions, with possible scores ranging from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. The number of participants with score changes (end of treatment - baseline) in DLQI overall score from baseline to end of treatment <=-5 and >-5 are presented.
  • Change From Baseline in EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) at End of Treatment [ Time Frame: Baseline and end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    The EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) is a standardized instrument for use as a measure of health outcome. The EQ-VAS asks for a judgment of the overall health status assessed by the participant her/himself. The 20-cm visual analog scale (VAS) has endpoints labeled "best imaginable health state" and "worst imaginable health state" that are anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS, which best represents their own health on that day; higher scores indicate a better health state. The median (range) of the change, defined as EQ-VAS at end of treatment minus EQ-VAS at baseline, is presented.
  • Change From Baseline in Index Value at End of Treatment [ Time Frame: Baseline and end of treatment, up to 12 weeks ] [ Designated as safety issue: No ]
    The EuroQol Group Questionnaire-5 Dimensions-5 Levels (EQ-5D-5L) is a standardized instrument for use as a measure of health outcome. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status. It is used to assess the level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension is evaluated using 5 levels: "no problems" (level 1), "slight problems" (level 2), "moderate problems" (level 3), "severe problems" (level 4), and "extreme problems" (level 5). A scoring formula developed by EuroQol Group calculates a single index value from the results from all 5 domains along a continuum of 0 (death) to 1 (full health). The median (range) change, defined as the index value at end of treatment minus the index value at baseline, is presented.
  • Safety and tolerability of topical Azelaic Acid Foam 15% [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
    Evaluation of all Adverse Events
  • Assess self-reported outcome parameters [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Collection of subject's global assessments on treatment response and tolerability as well as subject's opinion on cosmetic parameters
  • Assessment of effect of Azelaic Acid Foam (15%) and vehicle on parameters of quality of life in papulopustular rosacea [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Evaluation by using different Quality of Life questionnaires
Not Provided
Not Provided
 
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea
The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea compared to its vehicle.

To determine the efficacy of AzA foam, 15% compared to vehicle topically applied twice daily in papulopustular rosacea evaluated by therapeutic success rate according to Investigators Global Assessment (IGA) and change in inflammatory lesion count from baseline to end of treatment.

Evaluation of all adverse events will be covered in Adverse Events section.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Papulopustular Rosacea
  • Drug: Azelaic acid foam, 15% (BAY39-6251)
    Azelaic acid twice daily topical application
  • Drug: Vehicle foam
    twice daily topical application
  • Experimental: Azelaic acid foam, 15% (BAY39-6251)
    0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.
    Intervention: Drug: Azelaic acid foam, 15% (BAY39-6251)
  • Placebo Comparator: Vehicle foam
    0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.
    Intervention: Drug: Vehicle foam
Draelos ZD, Elewski BE, Harper JC, Sand M, Staedtler G, Nkulikiyinka R, Shakery K. A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. Cutis. 2015 Jul;96(1):54-61.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
961
January 2014
January 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of papulopustular rosacea
  • Free of any clinically significant disease, which could interfere with the study
  • Male or female subject aged ≥ 18 years
  • Willingness of subject to follow all study procedures
  • Signed written informed consent before any study-related activities are carried out

Exclusion Criteria:

  • Subjects who are known to be non-responders to azelaic acid
  • Presence of dermatoses that might interfere with rosacea diagnosis
  • Ocular rosacea; phymatous rosacea; subjects with plaque-type rosacea lesions, papulopustular rosacea that requires systemic treatment
  • Topical use of any prescription or non-prescription medication to treat rosacea within 6 weeks prior to randomization and throughout the study
  • Systemic use of any prescription or non-prescription medication to treat rosacea (Retinoids within 6 months, Tetracycline within 2 months, Corticosteroids, erythromycin, azithromycin, and/or metronidazole within 4 weeks) prior to randomization and throughout the study
  • Facial laser surgery for telangiectasia (or other conditions) within 6 weeks prior to randomization
  • Known hypersensitivity to any ingredients of the investigational product formulation
  • Participation in another clinical research in parallel or within the last 4 weeks before randomization in this study
  • Any condition or therapy that in the investigator's opinion may pose a risk to the subject or that could interfere with any evaluation in the study
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01555463
16080, 1401846
Not Provided
Not Provided
Not Provided
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP